BIOCRYST PHARMACEUTICALS INC (BCRX)

US09058V1035 - Common Stock

7.63  +0.45 (+6.27%)

Premarket: 7.59 -0.04 (-0.52%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (7/16/2024, 7:11:11 PM)

Premarket: 7.59 -0.04 (-0.52%)

7.63

+0.45 (+6.27%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month34.57%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.57B
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BCRX Daily chart

Company Profile

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 531 full-time employees. The firm focuses on oral treatments for rare diseases, in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), BCX9930, BCX9250, PERAMIFLU (peramivir injection), galidesivir, and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. BCX9930 is an oral, potent, and selective small molecule inhibitor of Factor D. Galidesivir is a broad-spectrum antiviral that is active against viral families.

Company Info

BIOCRYST PHARMACEUTICALS INC

4505 Emperor Blvd Ste 200

Durham NORTH CAROLINA 27703

P: 19198591302

CEO: Jon P. Stonehouse

Employees: 531

Website: https://www.biocryst.com/

BCRX News

News Imagea day ago - Market News VideoInteresting BCRX Put And Call Options For August 16th
News Image8 days ago - BioCryst Pharmaceuticals, Inc.ORLADEYO® (berotralstat) Approved in Peru

RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General...

News Image15 days ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., July 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Imagea month ago - BioCryst Pharmaceuticals, Inc.BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation...

News Image2 months ago - BioCryst Pharmaceuticals, Inc.BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis...

News Image2 months ago - Market News VideoTop Buys by Top Brass: Chief Financial Officer Doyle's $202.2K Bet on BCRX

BCRX Twits

Here you can normally see the latest stock twits on BCRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example